GP5 and cervical cancer: HPVs have been identified in 92.91% of a large series of cervical cancers collected internationally using PCR assays, of which 55 negative samples were tested again using HPV consensus GP5+/6+, E7 type-specific and CPI/II primers, where 72.7% were found to be positive for HPV.